Skip to main content

Advertisement

SpringerLink
Log in

Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

The aim of the study is to evaluate the use of beta-blockers in chronic heart failure (CHF) and the extent of heart rate reduction achieved in clinical practice and to determine differences in outcome of patients who fulfilled select inclusion criteria of the SHIFT study according to resting heart rate modulated by beta-blocker therapy. We evaluated an all-comer population of our dedicated CHF outpatient clinic between 2006 and 2010. For inclusion, individually optimized doses of guideline-recommended pharmacotherapy including beta-blockers had to be maintained for at least 3 months and routine follow-up performed at our outpatient CHF-clinic thereafter. Treatment dosages of beta-blockers, and demographic and clinical profiles including resting heart rate were assessed. The outcome of patients who fulfilled select inclusion criteria of the SHIFT study (left-ventricular ejection fraction (LVEF) ≤35 %, sinus rhythm, NYHA II–IV) and were followed-up for at least 1 year was stratified according to resting heart rates: ≥75 versus <75 bpm and ≥70 versus <70 bpm. The composite primary endpoint was defined as all-cause death or hospital admission for worsening heart failure during 12-month follow-up. In total, 3,181 patients were assessed in regard to treatment dosages of beta-blockers, and demographic and clinical profiles including resting heart rate. Of the overall studied population, 443 patients fulfilled all inclusion criteria and entered outcome analysis. Median observation time of survivors was 27.5 months with 1,039.7 observation-years in total. Up-titration to at least half the evidence-based target dose of beta-blockers was achieved in 69 % and full up-titration in 29 % of these patients. Patients with increased heart rates were younger, more often male, exhibited a higher NYHA functional class and lower LVEF. The primary endpoint occurred in 21 % of patients in the ≥70 bpm group versus 9 % of patients in the group with heart rates <70 bpm (p <0.01). Likewise, comparing the groups ≥75 and <75 bpm, the primary endpoint was significantly increased in the group of patients with heart rates ≥75 bpm 27 vs. 12.2 %; p < 0.01). 5-year event-free survival was significantly lower among patients with heart rates ≥70 bpm as compared to those with <70 bpm (log-rank test p < 0.05) and among patients in the ≥75 bpm group versus <75 bpm group (log-rank test p < 0.01). In conclusion, in clinical practice, 53 % of CHF patients have inadequate heart rate control (heart rates ≥75 bpm) despite concomitant beta-blocker therapy. In this non-randomized cohort, adequate heart rate control under individually optimized beta-blocker therapy was associated with improved mid- and long-term clinical outcome up to 5 years. As further up titration of beta-blockers is not achievable in many patients, the administration of a selective heart rate lowering agent, such as ivabradine adjuvant to beta-blockers may pose an opportunity to further modulate outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR (2000) Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36(7):2072–2080 (pii:S0735-1097(00)01006-8)

    Article  PubMed  CAS  Google Scholar 

  2. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR (1994) Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24(5):1310–1320 (pii:0735-1097(94)90114-7)

    Article  PubMed  CAS  Google Scholar 

  3. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, Haass M (2002) Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 39(10):1615–1622 (pii:S0735109702018405)

    Article  PubMed  CAS  Google Scholar 

  4. Sin DD, McAlister FA (2002) The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 113(8):650–656 (pii:S0002934302013463)

    Article  PubMed  CAS  Google Scholar 

  5. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17):2194–2199

    Article  PubMed  Google Scholar 

  6. Jost A, Rauch B, Hochadel M, Winkler R, Schneider S, Jacobs M, Kilkowski C, Kilkowski A, Lorenz H, Muth K, Zugck C, Remppis A, Haass M, Senges J (2005) Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study. Eur Heart J 26(24):2689–2697. doi:10.1093/eurheartj/ehi4733

    Article  PubMed  CAS  Google Scholar 

  7. Foody JM, Farrell MH, Krumholz HM (2002) beta-Blocker therapy in heart failure: scientific review. JAMA 287(7):883–889 (pii:jsr10002)

    Article  PubMed  CAS  Google Scholar 

  8. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26(11):1115–1140. doi:10.1093/eurheartj/ehi204

    Article  PubMed  Google Scholar 

  9. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112(12):e154–e235. doi:10.1161/CIRCULATIONAHA.105.167586

    Article  PubMed  Google Scholar 

  10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53(15):e1–e90. doi:10.1016/j.jacc.2008.11.013

    Article  PubMed  Google Scholar 

  11. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29(19):2388–2442. doi:10.1093/eurheartj/ehn309

    Article  PubMed  CAS  Google Scholar 

  12. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson P, Le Pen C (2005) Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26(16):1653–1659. doi:10.1093/eurheartj/ehi251

    Article  PubMed  Google Scholar 

  13. Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, Angermann CE (2008) Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail 10(12):1236–1245. doi:10.1016/j.ejheart.2008.09.008

    Article  PubMed  Google Scholar 

  14. Franke J, Zugck C, Wolter JS, Frankenstein L, Hochadel M, Ehlermann P, Winkler R, Nelles M, Zahn R, Katus HA, Senges J (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 101(1):1–10. doi:10.1007/s00392-011-0348-6

    Article  PubMed  Google Scholar 

  15. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Bohm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100(1):11–19. doi:10.1007/s00392-010-0207-x

    Article  PubMed  Google Scholar 

  16. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50(9):823–830. doi:10.1016/j.jacc.2007.04.079

    Article  PubMed  Google Scholar 

  17. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885. doi:10.1016/S0140-6736(10)61198-1

    Article  PubMed  CAS  Google Scholar 

  18. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894. doi:10.1016/S0140-6736(10)61259-7

    Article  PubMed  Google Scholar 

  19. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000597/human_med_000995.jsp&mid=WC0b01ac058001d124&jsenabled=true

  20. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841–842

    Article  PubMed  CAS  Google Scholar 

  21. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA (2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26(21):2259–2268. doi:10.1093/eurheartj/ehi386

    Article  PubMed  CAS  Google Scholar 

  22. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103(10):1428–1433

    Article  PubMed  CAS  Google Scholar 

  23. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784–794 (pii:150/11/784)

    PubMed  Google Scholar 

  24. Porapakkham P, Krum H (2010) Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure? Cardiovasc Ther 28(2):93–100. doi:10.1111/j.1755-5922.2010.00136.x

    Article  PubMed  CAS  Google Scholar 

  25. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H (2002) Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40(3):491–498 (pii:S0735109702019708)

    Article  PubMed  CAS  Google Scholar 

  26. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L (2010) EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 12(10):1076–1084. doi:10.1093/eurjhf/hfq154

    Article  PubMed  Google Scholar 

  27. de Groote P, Isnard R, Assyag P, Clerson P, Ducardonnet A, Galinier M, Jondeau G, Leurs I, Thebaut JF, Komajda M (2007) Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 9(12):1205–1211. doi:10.1016/j.ejheart.2007.09.008

    Article  PubMed  Google Scholar 

  28. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, Mehra M, O’Connor CM, Reynolds D, Walsh MN (2007) Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. Am Heart J 154(1):12–38. doi:10.1016/j.ahj.2007.03.030

    Article  PubMed  Google Scholar 

  29. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J (2003) The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24(5):464–474 (pii:S0195668X02007005)

    Article  PubMed  CAS  Google Scholar 

  30. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999). Lancet 353 (9169):2001–2007 (pii:S0140673699044402)

    Google Scholar 

  31. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial (1999). Lancet 353 (9146):9–13 (pii:S0140673698111819)

  32. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler–Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215–225. doi:10.1093/eurheartj/ehi115

    Article  PubMed  CAS  Google Scholar 

  33. Gheorghiade M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC (2012) Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail 18(1):9–17. doi:10.1111/j.1751-7133.2011.00250.x

    Article  PubMed  CAS  Google Scholar 

  34. Asghar H, Rahko PS (2010) Quality of heart failure management: a comparison of care between a comprehensive heart failure program and a general cardiology practice. Congest Heart Fail 16(2):65–70. doi:10.1111/j.1751-7133.2009.00136.x

    Article  PubMed  Google Scholar 

  35. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P (2003) Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J 24(6):552–559 (pii:S0195668X02007431)

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

C.Z. has received speaker′s honoraria from SHL Telemedizin, Servier, Novartis, Pfizer and AstraZenica. All other authors have declared no conflicts related to this research.

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Jennifer Franke, Jan Sebastian Wolter, Lillian Meme, Jeannette Keppler, Ramon Tschierschke, Hugo A. Katus & Christian Zugck

Authors
  1. Jennifer Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Sebastian Wolter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lillian Meme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeannette Keppler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ramon Tschierschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hugo A. Katus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian Zugck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Zugck.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 77 kb)

Supplementary material 2 (TIFF 268 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franke, J., Wolter, J.S., Meme, L. et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?. Clin Res Cardiol 102, 23–31 (2013). https://doi.org/10.1007/s00392-012-0489-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-012-0489-2

Keywords

Search

Navigation